Cargando…
Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera(®) was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera(®) combine...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789871/ https://www.ncbi.nlm.nih.gov/pubmed/31362406 http://dx.doi.org/10.3390/ph12030114 |